Infliximab Biosimilar (Genor Biopharma)

Product Name :
Infliximab Biosimilar (Genor Biopharma)

Search keywords :
Infliximab

drugId :
null

Target Vo:
Tumor necrosis factor α

Target Vo Short Name :
TNFα

Moa_Name:
Tumor necrosis factor α inhibitors

First Approval Country :
Mainland China

First Approval Date Filter:
2022

Origin Company_Name :
Genor Biopharma Co Ltd

Active Company_Name :
Yuxi Genor Biotechnology Co Ltd

Active Indication_Name:
Crohn Disease

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Approved

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Histone H3 (acetyl K27) Antibody
beta Tubulin Antibody (YA839)
MRP2/ABCC2 Antibody: MRP2/ABCC2 Antibody is an unconjugated, approximately 174 kDa, rabbit-derived, anti-MRP2/ABCC2 polyclonal antibody. MRP2/ABCC2 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, background without labeling.

Author: Betaine hydrochloride

Related Posts